NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Rhea-AI Summary
NeuroSense (Nasdaq: NRSN) received Nasdaq notification letters on April 2, 2026, for noncompliance with the $1.00 minimum bid rule and the $35M minimum market value of listed securities (MVLS) rule after 30 consecutive business days below each threshold.
These notices do not affect current listing or trading. The company has until September 29, 2026 (180 days) to regain compliance by meeting each metric for 10 consecutive business days and is evaluating actions to restore compliance focused on long-term shareholder value.
Positive
- Listing remains active with no immediate trading suspension
- 180-day compliance period until September 29, 2026 to regain listing standards
- Company is actively evaluating corrective actions supportive of long-term shareholder value
Negative
- Closing bid below $1.00 for 30 consecutive business days (Feb 18–Mar 31, 2026)
- MVLS below $35 million for 30 consecutive business days (Feb 18–Mar 31, 2026)
- Failure to regain standards by Sep 29, 2026 could risk Nasdaq delisting
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Clinical data presentation | Positive | -8.7% | New PrimeC ALS clinical and biomarker data presented at AD/PD 2026. |
| Mar 18 | Press release correction | Neutral | -8.7% | Corrected announcement regarding upcoming PrimeC ALS data presentation. |
| Mar 16 | Phase 2b trial results | Positive | +9.5% | JAMA Neurology publication of PARADIGM Phase 2b results showing clinical benefit. |
| Feb 18 | Survival data update | Positive | -2.9% | PARADIGM survival analysis showing 65% reduced death risk with PrimeC. |
| Jan 21 | IP/patent grant | Positive | +9.7% | U.S. patent granted for PrimeC combination therapy in Alzheimer’s disease. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive clinical and IP updates have produced mixed price reactions, with several instances where strong data coincided with negative or muted moves.
Over the past few months, NeuroSense reported multiple positive milestones, including a U.S. patent extending PrimeC-related protection through 2043 and statistically significant survival and functional benefits in the PARADIGM Phase 2b ALS program. JAMA Neurology publication and new data presentations supported advancement toward a Phase 3 PARAGON trial. Despite these developments, price reactions were inconsistent, with both gains above 9% and declines after favorable updates. Today’s Nasdaq noncompliance notice comes against this backdrop of fundamental progress but ongoing market pressure.
Key Terms
minimum bid price regulatory
market value of listed securities regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
- Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
- The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value
The first notification letter indicated that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
The second notification letter indicated that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed securities to maintain a minimum market value of listed securities ("MVLS") of
These notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq. The Company's ordinary shares and warrants will continue to trade on The Nasdaq Capital Market under the symbols "NRSN" and "NRSNW," respectively.
In accordance with Nasdaq Listing Rules, the Company has a compliance period of 180 calendar days, or until September 29, 2026, to regain compliance with both the minimum bid price requirement and the MVLS requirement. To regain compliance, the Company's ordinary shares must maintain a closing bid price of at least
The Company continues to actively monitor the closing bid price of its ordinary shares and its MVLS and is evaluating available actions to regain compliance with Nasdaq's continued listing requirements, with a clear focus on initiatives that support and enhance long-term shareholder value.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, reporting of data, meetings and regulatory decisions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-receipt-of-nasdaq-notifications-regarding-minimum-bid-price-and-market-value-requirements-302733781.html
SOURCE NeuroSense